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AbstrAct
Thiopurines are proven agents in the treatment of 
Crohn’s disease. While pancreatitis is recognised 
as an adverse event associated with therapy, 
the effect size and morbidity of thiopurine- 
induced pancreatitis is not known. The aim of 
this systematic review and meta- analysis was to 
quantify the risk of pancreatitis with azathioprine 
and 6- mercaptopurine (6- MP) within Crohn’s 
disease. We searched six electronic databases 
from inception to 29 October 2019. The primary 
outcomes measures were the occurrence of 
pancreatitis. We calculated pooled OR with 
corresponding 95% CIs for risk of pancreatitis. A 
number needed to harm analysis was performed. 
The search identified 4418 studies, of which 25 
randomised controlled trials met the criteria for 
inclusion. The number of patients treated with 
azathioprine to cause an episode of pancreatitis 
was 36 (induction of remission) and 31 
(maintenance of remission).The risk of pancreatitis 
in patients receiving azathioprine across all 
contexts was 3.80%, compared with a control 
risk of 0.2% (placebo) and 0.5% (5- aminosalicylic 
acid agents). There was no difference seen 
between 6- MP and placebo, although this was a 
low certainty result due to imprecision from very 
low event numbers and patient numbers. There 
is a probably increased occurrence of pancreatitis 
when azathioprine is used in Crohn’s disease 
(moderate certainty), with incidence overall 
approximately 3.8%. Most cases are mild and 
resolve on cessation of therapy and no mortality 
was reported. There was no increased occurrence 
seen when using 6- MP, although this is a low 
certainty finding. PROSPERO prior to the study 
(CRD42019138065).
IntroductIon
Corticosteroids, representing the 
mainstay of induction treatment for 
moderate- to- severe Crohn’s disease (CD), 
are inappropriate long- term agents in the 
maintenance of remission due to their 
adverse effect profile.1 Furthermore, corti-
costeroid dependency following induction 
with steroids in patients with CD occurs 
frequency. Population- based studies evalu-
ating the natural history of steroid- treated 
CD identified that 28%–36% of patients are 
steroid dependent at 1 year, with a further 
20%–22% labelled as steroid resistant.2 
Corticosteroid dependency in patients 
with CD is a major clinical problem, 
in which immunomodulation therapy 
with purine analogue therapy represents 
standard practice for maintenance of remis-
sion.3 4 Azathioprine (AZA) and its metab-
olite 6- mercaptopurine (6- MP) are thera-
peutic agents with proven efficacy in this 
context for treating CD,5 6 through their 
ability to obstruct rapid cellular prolifer-
ation in lymphocyte differentiation, thus 
limiting inflammatory response.7
Well- recognised dose- dependent adverse 
events associated with AZA and 6- MP 
include myelosuppression and hepato-
toxicity, which often resolve with dose 
reduction. These adverse events rarely 
necessitate termination of therapy.8 Idiosyn-
cratic adverse drug reactions (ie, intractable 
nausea, malaise, fever without leucopenia, 
arthralgia and acute pancreatitis), while 
more common in frequency than dose- 
dependent reactions, often demand discon-
tinuation of the offending medication.4
Pancreatitis has long been considered 
in the context of purine analogue use for 
CD. While the exact mechanism of AZA- 
induced pancreatitis remains unknown, the 
relationship appears to be dose- independent 
(idiosyncratic) with no correlation to 
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myelosuppression, suggesting the aetiology is indepen-
dent of thiopurine methyltransferase activity. A delayed 
type II or IV allergic reaction or immune- mediated 
genetic disposition has been postulated, with the former 
supported by the fact rechallenge of AZA results in 
recurrence of symptoms.9 Of interest, when AZA is used 
within other clinical settings, acute pancreatitis is seldom 
seen. AZA is not reported to induce pancreatitis when 
used in the context of renal transplantation, rheumatoid 
arthritis, autoimmune hepatitis, lupus erythematous, 
lupus nephritis or antineutrophil cytoplasmic antibodies 
(ANCA)- positive vasculitis.10–15
International guidelines recommend the fulfilment 
of two criteria from the following as diagnostic for 
acute pancreatitis: abdominal pain consistent with 
the diagnosis, serum lipase/amylase values exceeding 
three times the upper limit of normal, and radiolog-
ical imaging of the abdomen consistent with pancre-
atitis.4 16 17
A large- prospective trial conducted in Denmark 
between 1977 and 1992 (n=15 526) identified the 
incidence of acute pancreatitis to be 4.3 times more 
frequent in those with CD, and 2.1 times more 
frequent in those with ulcerative colitis, as compared 
with healthy counterparts.18 Weersma et al reported 
an incidence of 4.9% in a retrospective review of 
224 patients with CD,19 and more recently Teich et 
al prospectively detected a 8.9% incidence rate of 
pancreatitis in 338 Crohn’s patients.4
The natural course of AZA- induced pancreatitis is 
often mild,18 as was the case in all patients in both 
these recent studies, developing approximately 3–4 
weeks after initiation of treatment.4 19 In general, the 
risk of repeat pancreatitis with thiopurine rechallenge 
or thiopurine switch is high; as such, rechallenge in 
the context of pancreatitis is not recommended and 
therefore occurrence of pancreatitis will necessitate 
permanent cessation of purine therapy. Tioguanine as 
an alternative to AZA and 6- mercaptopurine has been 
noted as successful in avoiding pancreatitis.20
In reviewing the clinical recommendations, as 
published by seven leading national and interna-
tional expert groups, five recognise pancreatitis as a 
side effect of AZA and 6- MP,21–26 with two making 
no reference.27 28 None of the publications estimate 
the burden or attempt to quantify the effect size of 
thiopurine- induced pancreatitis and not all advise 
what to do after such an adverse event has occurred. 
While it is unequivocal thiopurines are associated with 
pancreatitis within the context of CD, an accurate esti-
mation of the risk in different clinical scenarios is not 
known. The reported morbidity and mortality associ-
ated with such cases is also not clearly established.
The objective of this systematic review is to deter-
mine, based on the available randomised controlled 
trial (RCT) evidence, the risk of pancreatitis with thio-
purines within CD across a number of common clin-
ical situations within CD.
Methods
A systematic review, completed in- line with the 
Cochrane methodology and reported in- line with the 
Preferred Reporting Items for Systematic Reviews and 
Meta- Analyses (PRISMA) statement is presented.29 30 
The research protocol was registered with PROSPERO 
prior to the study (CRD42019138065).31
criteria for considering studies for this review types of 
studies
RCTs were considered for inclusion.
Types of participants
Patients of any age with CD having therapy for induc-
tion or maintenance of remission were considered for 
inclusion.
Types of interventions
Studies that evaluated AZA or 6- MP in comparison to 
placebo, no intervention or any other pharmacological 
agent were eligible for inclusion. The study follow- up 
period was required to be at least 3 months.
types of outcome measures
Primary outcomes
The primary outcome measure was the occurrence of 
pancreatitis, as defined by the reporting study. Explicit 
reference to the incidence of pancreatitis was not a 
prerequisite for inclusion within this review.
Secondary outcomes
Secondary outcomes included withdrawal of therapy 
due to pancreatitis and pancreatitis- related mortality.
search methods for identification of studies
Electronic searching
We searched the following electronic databases from 
inception to 29 October 2019 for relevant studies: 
PubMed, MEDLINE, EMBASE, Cochrane Central 
Register of Controlled Trials,  ClinicalTrials. gov and 
the WHO trial registry. The search strategy was not 
limited by language. The search strategy used for each 
database is reported in online supplementary appendix 
1.
Searching other resources
The references of all identified studies were scrutinised 
to identify further studies for inclusion.
data collection and analysis
The abstracts identified from the searches were 
reviewed by two authors (CG- C and MG). If the refer-
ence appeared potentially relevant, a full copy of the 
study was obtained.
Selection of studies
Papers (or abstracts) that appeared to be potentially 
relevant were identified by two authors (CG- C and 
MG). The authors (CG- C and MG), after reading 
 on June 17, 2020 at B
V
A
. P
rotected by copyright.
http://fg.bm
j.com
/
F
rontline G
astroenterol: first published as 10.1136/flgastro-2020-101405 on 11 June 2020. D
ow
nloaded from
 
Gordon M, et al. Frontline Gastroenterology 2020;0:1–14. doi:10.1136/flgastro-2020-101405  3
EduCAtIoN
the full texts, independently assessed the eligibility of 
all trials identified using the inclusion criteria above. 
Disagreement among authors was discussed and agree-
ment reached by consensus.
Data extraction and management
A data extraction template was developed to extract 
information on the characteristics and results of 
included studies. Two authors (CG- C and MG) inde-
pendently extracted and recorded data. In situations 
where the study reports on adverse events associated 
with treatment but fails to report on the incidence of 
acute pancreatitis, then the incidence of pancreatitis 
was inferred to be zero.
Assessment of risk of bias in included studies
The methodological quality of the included studies 
was independently evaluated by two authors (CG- C 
and MG) using the Cochrane risk of bias tool.32 Disa-
greements were resolved by consensus. The overall 
quality of the evidence supporting the primary 
outcomes was evaluated using the Grading of Recom-
mendations Assessment, Development and Evaluation 
(GRADE) approach,32 which appraises the quality of 
a body of evidence based on the extent to which one 
can be confident that an estimate of effect or associ-
ation reflects the item being assessed. The different 
quality ratings are interpreted as the likelihood that 
future research would change the effect estimate. The 
overall quality of the evidence for each outcome was 
determined after considering each of these factors and 
graded as high (further research unlikely to change 
confidence in the estimate of effect), moderate, low 
or very low (any estimate of effect is very uncertain).
statistical analysis
The Cochrane Collaboration review manager 
(RevMan) software (V.5.3.5) was used for data anal-
ysis. We calculated the OR and corresponding 95% CI 
for dichotomous outcomes. We pooled studies for 
meta- analysis when treatment context and interven-
tions were deemed to be sufficiently similar (as deter-
mined by consensus) using a random- effects model. An 
intention- to- treat analysis was performed, including all 
randomised patients in analysis. However, as the focus 
was on a specific adverse effect (pancreatitis), and trial 
governance would dictate the reporting of such serious 
adverse events, all drop- outs were not assumed to have 
withdrawn due to pancreatitis. The number needed to 
harm in relation to the primary outcome was calcu-
lated using the method as outlined in the Cochrane 
methodological handbook.33
When cross- over trials were included, data from 
the first phase of the study were extracted for anal-
ysis (ie, before the cross- over occurred), provided 
that the primary outcomes presented were delineated 
temporally between precross- over and postcross- over 
checkpoints. Separate analyses were conducted for 
comparisons between AZA or 6- MP versus placebo, 
and AZA or 6- MP versus individual active compara-
tors (eg, infliximab, mesalazine and methotrexate).
Assessment of heterogeneity
Heterogeneity among trial results was assessed by 
visual inspection of forest plots and by calculating 
χ2 (a p<0.10 was regarded as statistically significant 
heterogeneity). The I2 statistic was calculated to quan-
tify the effect of heterogeneity across studies. We 
conducted sensitivity analyses as appropriate to inves-
tigate heterogeneity. For example, if pooled analysis 
showed statistically significant heterogeneity and a 
visual inspection of the forest plot identified studies 
that may have contributed to this, then the analysis was 
repeated excluding these studies to see if this explained 
the heterogeneity.
Subgroup analysis
Subgroup analyses were performed to reflect the 
different clinical contexts in which thiopurines are used 
within the management of CD, in which three patient 
groups were identified as being clinically distinct, as 
determined through consensus. Group 1 includes non- 
surgical patients receiving treatment with thiopurines 
for the maintenance of remission in whom disease 
management was purely pharmacological. Group 2 
includes patients with disease in remission at the onset 
of the trial following surgery for CD. Group 3 includes 
non- surgical patients receiving treatment with thiopu-
rines for active CD, in whom disease management was 
pharmacological.
results
description of studies
The results of the electronic search conducted on the 
29 October 2019 are reported in the PRISMA flow 
diagram (figure 1). A total of 4418 studies were identi-
fied from the search. Following removal of duplicates, 
3319 studies were screened, of which 257 proceeded 
to abstract screening. Of these, 41 studies were judged 
to be potentially relevant and subjected to full text 
review. A total of 25 studies were found to meet the 
inclusion criteria.34–58 Sixteen studies were excluded at 
the full- text review. Six studies failed to investigate a 
thiopurine in isolation.59–64 Three studies did not focus 
specifically on Crohn’s as a disease entity.65–67 Three 
studies failed to demonstrate randomised controlled 
study methodologies.68–70 A further four studies were 
excluded due to being a withdrawal trial, time to 
follow- up of less than 3 months, reporting a subanal-
ysis of a study already meeting the inclusion criteria, 
and analysing both AZA and 6- MP within the thiopu-
rine arm.71–74
Twenty- one studies compared AZA to a 
comparator. Eleven studies compared AZA to 
placebo.34 35 38–42 44 50 52 56 Four studies compared 
AZA to mesalazine.43 46–48 Two studies compared 
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Figure 1 PRISMA study flow diagram. PRISMA, Preferred Reporting 
Items for Systematic Reviews and Meta- Analyses.
AZA to infliximab.36 49 One study compared AZA to 
budesonide37; to adalimumab53 and to methotrexate.54 
The study reported by Savarino included three inter-
vention arms: AZA, mesalazine and adalimumab.57
Four studies compared 6- MP to a comparator. Three 
studies study compared 6- MP to placebo.51 55 58 The 
study reported by Hanauer et al compared 6- MP to 
both placebo and mesalazine in a three- armed trial.45
Across the 25 RCTs meeting the inclusion criteria, 
a total of 2399 participants were included (thiopu-
rine arm=1151, comparator arm=1248). All but 
one trial included adult patients with CD, with only 
the trial reported by Markowitz focusing on a paedi-
atric population (average age=13.2 years).55 Eleven 
studies focused on patients with active disease, and 
the aim of treatment was induction of remission, 
followed by maintenance of remission (nine AZA 
vs comparator studies; two 6- MP vs comparator 
studies).34 39 41 42 48–50 52 54 55 58 Seven studies focused 
on non- surgical patients in remission, and the aim 
of treatment was maintenance of remission (seven 
AZA vs comparator studies; zero 6- MP vs compar-
ator studies).35 37 38 40–42 44 Nine studies focused on 
the maintenance of remission postsurgery (seven 
AZA vs comparator studies; two 6- MP vs comparator 
studies).35 36 43 45–47 51 53 57
Risk of bias
Details of the risk of bias assessment for each study 
are presented within the online supplementary mate-
rials. The risk of bias related to random sequence 
generation (selection bias) was deemed to be ‘low risk’ 
in 15 studies (60%) and ‘unclear risk’ in 10 studies 
(40%). The bias attributed to allocation concealment 
(selection bias) was classified as ‘low risk’ in 12 studies 
(48%) and ‘unclear risk’ in 13 studies (52%). Blinding 
of participants (performance bias) was deemed to be 
‘low risk’ in 13 studies (52%), ‘unclear risk’ in three 
studies (12%) and ‘high risk’ in nine studies (36%). 
The reason for such ‘high risk’ classifications included 
failing to blind the participants and/or investigators to 
the intervention.35–37 43 48 53 54 56 57 Incomplete outcome 
data (attrition bias) was deemed to be ‘low risk’ in 22 
studies (88%) and ‘unclear risk’ in three studies (12%). 
The bias attributed to selective reporting (reporting 
bias) was classified as ‘low risk’ in 23 studies (92%), 
‘unclear risk’ in one study (4%) and ‘high risk’ in one 
study (4%). The study as reported by López- Sanromán 
et al was found to be at ‘high risk’ of reporting bias 
by failing to report on all outcomes as prespecified in 
trial protocol.53 In summary, 5 studies were assessed to 
be at a ‘low risk’ of bias,39 45 46 49 51 11 were ‘unclear 
risk’,34 38 40–42 44 47 50 52 55 58 and the remaining 9 were at 
a ‘high risk’ of bias.35–37 43 48 53 54 56 57
Primary outcome: incidence of pancreatitis
Two of the 25 included studies provided a case defi-
nition of acute pancreatitis.39 41 Panés et al defined 
pancreatitis as ‘elevation of amylase and lipase levels 
and cross- sectional imaging consistent with the 
diagnosis’.39 Summers et al defined pancreatitis as 
‘elevated serum amylase or lipase during an episode 
of abdominal pain’.41 The remaining 23 studies 
failed to provide a case definition of pancreatitis, 
even if pancreatitis was listed as a recorded adverse 
event of therapy. Eighteen studies (72%) explicitly 
state the incidence of pancreatitis within both treat-
ment arms.34 35 37 39 41 43–45 47 48 51 52 54–58 Seven studies 
(28%) provide no reference to acute pancreatitis when 
reporting adverse events36 38 40 42 49 50 53; and did not 
respond to requests for further information. As such, 
the incidence was inferred to be zero episodes in all 
treatment arms (table 1) given the strict governance 
reporting requirements of such studies.
safety analysis
A summary of results for AZA versus comparator 
studies is presented in table 2 and summary of findings 
in table 3. Across all patient groups, those receiving 
AZA had 21 episodes of pancreatitis, compared with 
one episode occurring in the placebo group, which 
was a statistically significant finding (OR 8.92, 95% CI 
2.61 to 30.54, p=0.0005; figure 2).
For patients receiving AZA for induction of remis-
sion, there were more cases of pancreatitis in those 
receiving AZA compared with placebo (OR 8.30, 
95% CI 1.44 to 47.71, p=0.02, low certainty evidence 
downgraded one level due to sparsity of data and one 
level due to inconsistency due to the short treatment 
lengths for induction of remission, see tables 2 and 3 
and figure 2). The number needed to harm was 32. For 
patients receiving AZA for maintenance of medically 
induced remission, there were more cases of pancre-
atitis in those receiving AZA compared with placebo 
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(OR 9.58, 95% CI 1.70 to 54.08, p=0.01, moderate 
certainty evidence, downgraded one level due to 
sparsity of data, see tables 2 and 3 and figure 2). The 
number needed to harm was 36. There was only one 
study considering postsurgical maintenance with no 
cases of pancreatitis, so no effect estimate could be 
calculated (table 2).
When comparing AZA to 5- aminosalicylic acid 
(5- ASA) agents, across all patient groups, AZA resulted 
in 11 episodes of pancreatitis, compared with one 
episode occurring in the mesalazine group, which was 
not found to be statistically significant (OR 3.42, 95% CI 
0.85 to 13.78, p=0.08, low certainty evidence, down-
graded two levels for imprecision due to low patient 
numbers, low event numbers and inconsistency due to 
variability in CIs, see table 2 and figure 3). Similarly, 
AZA when compared with budesonide, infliximab, 
adalimumab and methotrexate, failed to demonstrate 
statistical significance in favour of increased incidences 
of AZA- induced pancreatitis. There were two episodes 
of pancreatitis with AZA compared with no episodes in 
the budesonide arm (OR 5.41, 95% CI 0.25 to 116.5, 
p=0.28, see table 2). There we no episodes of pancre-
atitis in either the AZA or infliximab treatment arms. 
One episode of pancreatitis was found with AZA in 
comparison to zero episodes in the adalimumab treat-
ment arm (OR 3.00, 95% CI 0.11 to 79.13, p=0.51, 
see table 2). One episode of pancreatitis was found 
with AZA in comparison to zero episodes occurring 
with methotrexate treatment (OR 3.11, 95% CI 0.12 
to 79.87, p=0.49, see table 2).
Across all studies comparing AZA to comparator, 
there were 36 episodes of pancreatitis occurring in 
947 participants receiving AZA (incidence 3.80%), 
in comparison to 2 episodes of pancreatitis occurring 
in 1010 participants receiving comparator treatment 
(incidence 0.20%). The number needed to harm was 
27.8.
6-MP-induced pancreatitis
A summary of findings for 6- MP versus compar-
ator studies is presented in table 4. Across all patient 
groups, there were two episodes of pancreatitis in 
participants receiving 6- MP, in comparison to one 
episode occurring in participants receiving placebo. 
This was not found to be statistically significant (OR 
1.32, 95% CI 0.16 to 11.05, p=0.80, see table 4 and 
figure 4). Subgroup analysis did not show significance 
in patients with active disease treated medically (OR 
2.35, 95% CI 0.09 to 62.09, p=0.61) or in patients 
in remission post- surgery (OR 0.87, 95% CI 0.05 to 
14.14, p=0.92). There were no studies comparing 
6- MP to comparator in the context of maintaining 
medically induced remission, thus no effect estimate 
could be calculated.
Across all studies comparing 6- MP to comparator, 
there were two episodes of pancreatitis occurring in 
268 participants (incidence 0.75%), in comparison to 
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table 2 Azathioprine versus comparator
azathioprine Placebo
Or (95% ci)events total events total
Azathioprine versus placebo (all contexts) 21 438 1 504 8.92 (2.61 to 30.54)
p=0.0005
Azathioprine versus placebo (active disease—
medical)
11 200 0 210 8.30 (1.44 to 47.71)
p=0.02
Azathioprine versus placebo (maintenance of 
remission—medical)
10 198 1 253 9.58 (1.70 to 54.08)
p=0.01
Azathioprine versus placebo (maintenance of 
remission—surgical)
0 40 0 41 –
  azathioprine mesalazine Or (95% ci)
events total events total
Azathioprine versus mesalazine (all contexts) 11 207 1 199 3.42 (0.85 to 13.780)
p=0.08
Azathioprine versus mesalazine (active disease—
medical)
1 36 0 36 3.08 (0.12 to 78.27)
p=0.49
Azathioprine versus mesalazine (maintenance of 
remission—medical)
– – – – –
Azathioprine versus mesalazine (maintenance of 
remission—surgical)
10 171 1 163 3.46 (0.67 to 17.93)
p=0.14
  azathioprine Budesonide Or (95% ci)
events total events total
Azathioprine versus budesonide (all contexts) 2 38 0 39 5.41 (0.25 to 116.51)
p=0.28
Azathioprine versus budesonide (active disease—
medical)
– – – – –
Azathioprine versus budesonide (maintenance of 
remission—medical)
2 38 0 39 5.41 (0.25 to 116.51)
p=0.28
Azathioprine versus budesonide (maintenance of 
remission—surgical)
– – – – –
  azathioprine infliximab Or (95% ci)
events total events total
Azathioprine versus infliximab (all contexts) 0 181 0 180 –
Azathioprine versus infliximab (active disease—
medical)
0 169 0 170 –
Azathioprine versus infliximab (maintenance of 
remission—medical)
– – – – –
Azathioprine versus infliximab (maintenance of 
remission—surgical)
0 11 0 11 –
  azathioprine adalimumab Or (95% ci)
events total events total
Azathioprine versus adalimumab (all contexts) 1 56 0 61 3.00 (0.11 to 79.13)
p=0.51
Azathioprine versus adalimumab (active disease—
medical)
– – – – –
Azathioprine versus adalimumab (maintenance of 
remission—medical)
– – – – –
Azathioprine versus adalimumab (maintenance of 
remission—surgical)
1 56 0 61 3.00 (0.11 to 79.13)
p=0.51
  azathioprine methotrexate Or (95% ci)
events total events total
Azathioprine versus methotrexate (all contexts) 1 27 0 27 3.11 (0.12 to 79.87)
p=0.49
Azathioprine versus methotrexate (active disease—
medical)
1 27 0 27 3.11 (0.12 to 79.87)
p=0.49
Continued
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azathioprine Placebo
Or (95% ci)events total events total
Azathioprine versus methotrexate (maintenance of 
remission—medical)
– – – – –
Azathioprine versus methotrexate (maintenance of 
remission—surgical)
– – – – –
Incidence of pancreatitis.
table 2 Continued
table 3 GRADE summary of findings
aZa compared with placebo in crohn’s disease: a systematic review
Patient or population: patients with crohn’s disease
Setting: any
intervention: aZa
comparison: placebo
Outcomes
anticipated absolute effects* 
(95% ci)
relative effect
(95% ci)
No of 
participants
(studies)
certainty of the 
evidence
(GraDe) comments
risk with 
placebo risk with aZa
AZA versus Placebo - AZA 
versus Placebo (active disease—
medical)
0 per 1000 55 per 1000
(not estimated)
Or 8.30
(1.44 to 47.71)
410
(6 RCTs)
⨁⨁⨁◯
MODERATE†
AZA versus Placebo—AZA 
versus placebo (maintenance of 
remission—medical)
4 per 1000 37 per 1000
(7 to 177)
Or 9.58
(1.70 to 54.08)
451
(6 RCTs)
⨁⨁⨁◯
MODERATE†
GRADE Working Group grades of evidence. High certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a 
possibility that it is substantially different. Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different 
from the estimate of the effect. Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different 
from the estimate of effect.
*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and 
its 95% CI).
†Downgraded 1 level due to imprecision from sparsity of adverse events.
AZA, azathioprine; GRADE, Grading of Recommendations Assessment, Development, and Evaluation ; RCT, randomised controlled trial.
one episode of pancreatitis occurring in 238 partic-
ipants receiving comparator treatment (incidence 
0.42%). The number needed to harm was 303.
secondary outcomes
Withdrawal of therapy due to pancreatitis
Across the 36 participants reported to have developed 
pancreatitis secondary to AZA use across all clin-
ical contexts, 28 participants were withdrawn from 
the trial due to this event. In the trial reported by 
Cosnes et al, six of the seven cases of AZA- induced 
pancreatitis continued follow- up in their respective 
trials; however, treatment with AZA was stopped and 
the participants were commenced on methotrexate 
therapy.35 One of the six patients with AZA- induced 
pancreatitis reported by Summers continued AZA due 
to normalisation of abdominal pain and serum amylase 
levels.41 The patient with pancreatitis in the trial as 
reported by Ewe et al continued within the trial as he 
remained asymptomatic.52 The two participants with 
pancreatitis occurring in the comparator arms were 
withdrawn from the trials.35 46
In the two episodes of pancreatitis occurring in 
participants receiving treatment with 6- MP, only one 
participant reported by Mowat et al remained in the 
trial, despite developing ‘mild’ pancreatitis.51 The one 
comparator participants with pancreatitis was with-
drawn from the trial.51
Pancreatitis-related mortality
There were no reported deaths as a result of thio-
purine or comparator- induced pancreatitis across 
all included studies. Further details relating to the 
presentation, clinical course and sequelae of all 38 
thiopurine- induced pancreatitis cases is presented in 
table 4.
Of note, only nine of the included 25 studies explic-
itly state in the research methodologies that lipase 
and/or amylase levels were assessed during treat-
ment.37 43 45 47 52 54 55 57 58 Episodes of pancreatitis 
were identified within trial participants in seven of 
these nine studies.37 43 47 52 54 57 58 Of the 16 studies not 
explicitly declaring lipase and/or amylase monitoring 
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Figure 2 Forest plot—azathioprine versus placebo. AZA, azathioprine.
Figure 3 Forest plot—azathioprine versus mesalazine. AZA, azathioprine; M- H, Mantel- Haenszel.
during treatment, episodes of pancreatitis were identi-
fied in only six studies.35 39 41 46 48 51
dIscussIon
This review has shown with moderate certainty that 
the use of AZA to induce remission and maintain 
medical induced remission in CD is probably asso-
ciated with increased occurrence of pancreatitis. 
This GRADE rating suggests the results are probably 
unlikely to change with future studies. The number of 
patients treated to cause an episode of pancreatitis for 
induction therapy was 36 and for maintenance therapy 
was 31 patients. In the 947 participants receiving treat-
ment with AZA, 36 patients developed pancreatitis, 
corresponding with a pancreatitis incidence of 3.80%, 
compared with a control risk in placebo patients of 
just 0.2% and 0.5% in 5- ASA patients. For every 33 
patients treated with AZA for CD, an extra episode 
of thiopurine- induced pancreatitis would be expected. 
Within all these reported episodes, there was no 
reported mortality and while clarity of diagnostic 
criteria was difficult to ascertain, it appears that most 
cases were mild. As such, the clinical implications of 
these findings are to clarify the potential incidence of 
pancreatitis associated with AZA use and that in those 
cases withdrawal of therapy is likely, but the course 
otherwise appears to be mild.
The findings in 6- MP were different. In the post-
surgical remission context where there are two large 
trials by Hanauer et al and Mowat et al with 327 
participants showed no difference in pancreatitis inci-
dence,45 51 with just one case in the 6- MP and placebo 
groups, respectively. In induction of remission, there 
was a difference based on one case occurring in the 
6- MP group and none in the placebo. This led to no 
significant difference in incidence, However, as the 
numbers of studies and participants were much lower, 
this is a low certainty finding based on a difference in  on June 17, 2020 at B
V
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table 4 6- mercaptopurine versus comparator
6- mercaptopurine Placebo
Or (95% ci)events total events total
6- Mercaptopurine versus 
placebo (all contexts)
2 221 1 194 1.32 (0.16 to 11.05)
p=0.80
6- Mercaptopurine versus 
placebo (active disease—
medical)
1 46 0 42 2.35 (0.09 to 62.09)
p=0.61
6- Mercaptopurine versus 
placebo (maintenance of 
remission—medical)
– – – – –
6- Mercaptopurine versus 
placebo (maintenance of 
remission—surgical)
1 175 1 52 0.87 (0.05 to 14.14)
p=0.92
  6- mercaptopurine mesalazine Or (95% ci)
events total events total
6- Mercaptopurine versus 
mesalazine (all contexts)
0 47 0 44 –
6- Mercaptopurine versus 
mesalazine (active 
disease—medical)
– – – –   
6- Mercaptopurine versus 
mesalazine (maintenance of 
remission—medical)
– – – –   
6- Mercaptopurine versus 
mesalazine (maintenance of 
remission—surgical)
0 47 0 44 –
Incidence of pancreatitis.
Figure 4 Forest plot—6- mercaptopurine (6- MCP) versus placebo. M- H, Mantel- Haenszel.
just one case of pancreatitis. It is nevertheless difficult 
to ignore the stark difference between this and AZA.
Our findings provide clarity following a range of 
previously published observational studies suggesting 
the incidence of thiopurine- induced pancreatitis to be 
as high as 8.9%. The results of this systematic review 
and meta- analysis reveal a lower than previously 
demonstrated incidence of AZA- induced pancreatitis 
with a reasonably mild course, as well as what appears 
to be a better profile with 6- MP. It is not possible to tell 
whether in clinical practice cessation of therapy would 
be needed, as the study protocols of most trials require 
any such biochemical changes to lead to cessation, 
regardless of clinical symptoms.
The strength to this review is that all included 
studies were RCTs; as such, many of the biases limiting 
the generalisability of the previously discussed obser-
vational studies are reduced, meaning the results are 
more directly aligned with the scientific truth. Further-
more, this review provides insight into the risks for 
specific groups of patients, such as postsurgery and in 
the induction of remission. It is worth noting that the 
use of purine analogues to induce remission is contro-
versial in current practice but given the significant 
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table 5 Thiopurine- induced pancreatitis in leading Crohn’s disease guideline publications
Guideline reference to pancreatitis
Quantification of thiopurine- 
association pancreatitis risk
British Society of Gastroenterology consensus 
guidelines21
Published June 2019
Recognises that thiopurines are contraindicated in 
pancreatitis, even at a low dose, due to high chances for 
recurrence.
Does not state risk of occurrence on thiopurines.
No effect size estimate provided.
National Institute for Health and Care Excellence—
NG12922
Published May 2019
Recognises that thiopurines are contraindicated if a patient 
has experienced past episodes of pancreatitis.
Does not state risk of occurrence on thiopurines.
No effect size estimate provided.
American College of Gastroenterology clinical 
guideline23
Published April 2018
Recognises that thiopurines are associated with 
pancreatitis.
No effect size estimate provided.
Japanese Society of Gastroenterology clinical practice 
guidelines24
Published February 2018
Recognised pancreatitis as a side effect of azathioprine 
and 6- mercaptopurine (evidence level: A)
No effect size estimate provided.
European Crohn’s and Colitis Organisation consensus 
guideline25 26
Published September 2016
Recognises that thiopurines are contraindicated if a patient 
has previous experienced episodes of pancreatitis.
Does not state risk of occurrence on thiopurines.
No effect size estimate provided.
World Gastroenterology Organisation global 
guidelines27
Published August 2015
No reference. No effect size estimate provided.
American Gastroenterological Association Institute 
guideline28
Published December 2013
No reference. No effect size estimate provided.
RCT evidence base included in this review, inclusion 
of these studies was deemed to be appropriate.
In May 2019 and June 2019, both the National 
Institute for Health and Care Excellence and the 
British Society of Gastroenterology published their 
most up- to- date consensus- based clinical guidelines 
on the management of CD and inflammatory bowel 
disease, respectively (table 5).21 22 Both guidelines 
recognise that thiopurines are contraindicated in 
patients who have previously experienced pancreatitis, 
and should be avoided even at low doses.21 Neither 
guidelines quantify the effect size of thiopurine- 
associated pancreatitis risk for those without previous 
incidence and therefore do not propose surveillance or 
cessation of therapy if such primary cases occur. Simi-
larly, in clinical guidelines published in 2018 by the 
American College of Gastroenterology and the Japa-
nese Society of Gastroenterology, while pancreatitis is 
recognised as an adverse effect, no effect size estimate 
is provided.23 24 The most recent guidelines published 
by the World Gastroenterology Organisation and the 
American Gastroenterological Association fail to make 
any reference to AZA- induced pancreatitis.27 28 The 
British National Formulary did mention the risk of 
pancreatitis as uncommon with AZA, which according 
to their guidance suggests the incidence is between one 
in 100 and one in 1000 dose administrations, and is 
therefore not aligned with our findings.75 Review of 
this manuscript in draft has already led to a change in 
the guidance within the UK British National Formu-
lary in January 2020, now regarding the incidence of 
pancreatitis with AZA use as common. As with most 
treatments in CD, the benefits of therapy outweigh 
potential risks of adverse events and so this simply 
accurately reflects the incidence of this side effect with 
other well- recognised effects.
Purine analogues remain a mainstay treatment in 
CD as advocated by national and international soci-
eties.21 23–25 These findings are unlikely to lead to 
change in recommendations for their use. By the 
deployment of a robust systematic review method-
ology and the use of GRADE to assess the certainty of 
these key findings, we believe these results can be used 
by international societies and guideline committees 
to highlight this risk when counselling patients about 
other well- recognised adverse events, with a reliable 
incidence rate and associated clarity as to the likely 
severity of the course and its implications.
These conclusions are obviously limited by key 
elements within this review. First, the overall patient 
and event numbers led to a downgrading of the certainty 
of the findings due to imprecision. It is hard to justify 
future trials for just this purpose and this is a common 
issue with the GRADING of such adverse effect find-
ings, but future updates of this review may use trials 
of efficacy to inform revisions of this finding. This is 
particularly pertinent in the context of 6M6, which 
had far less trials, but appears to have a much better 
profile. Second, our analysis assumed all patients who 
left the trial and not explicitly stated to have pancre-
atitis did not in fact have the condition. This is not the 
usual position when considering drop- outs, but due 
to the clear governance on safety within randomised 
trials, this was believed to be a reasonable assumption, 
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but this may have had an impact on the results. Third, 
the paper has focused on CD. While these medications 
are used for ulcerative colitis, as they are not key ther-
apeutics for the condition, this has not formed a focus 
for the study. Finally, there has been a distinction made 
between the use of these medications as induction and 
maintenance therapy. To clinical readers, this may not 
seem clinically useful, but as research papers tend to 
define studies with one of these two purposes, we have 
had to specifically subgroup studies in this way. Finally, 
exploration of the specific risk factors or patient char-
acteristics that predispose to such side effects would 
be useful, but reporting was limited and this was not 
possible.
Future research may seek to clarify the severity 
of such cases of pancreatitis and study authors are 
encouraged to report these in line with the interna-
tional criteria, as well as other confounding factors 
that may increase risk. While pancreatitis is only one 
of several idiosyncratic adverse events related to thio-
purine intolerance, there may be elements of overlap 
with AZA- associated fever, arthritis and septic- shock 
clinical pictures following re- exposure. Human leuko-
cyte antigen (HLA)- typing has been demonstrated to 
be an important and accurate predictor of pancreatitis 
risk, which may represent an opportunity to more 
precisely advise patients prior to starting AZA.26 76 An 
understanding as to why thiopurine- induced pancre-
atitis is seen in the context of CD and not with similar 
increased incidence when purines are used in other 
contexts or appears less frequent with 6- MP is needed. 
The use of serum metabolite testing during purine use 
is common and included in a number of international 
guidelines. Exploration as to whether such monitoring 
reduces risk of such side effects is also needed.
conclusIon
This is the first Cochrane format systematic review 
to consider pancreatitis as an adverse event associ-
ated with purine analogue use in CD. The estimated 
the overall incidence of AZA- induced pancreatitis in 
randomised trials of Crohn’s patients to be nearly 
4% in patients receiving treatment, compared with a 
baseline risk of just 0.2%, with most cases mild and 
resolving after cessation of therapy. The difference 
between 6- MP and placebo was not significant. This 
finding should be of interest to patients, prescribers 
and policy- makers.
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